Table 1. Characteristics of the study population.
| Total (N=2254) | Male (N=1200) | Female (N=1054) | |
|---|---|---|---|
|
| |||
| Site: | |||
| Toronto, ON, Canada | 1362 (60.5%) | 791 (65.9%) | 571 (54.2%) |
| Vancouver, BC, Canada | 73 (3.2%) | 38 (3.2%) | 35 (3.3%) |
| Ann Arbor, MI, USA | 77 (3.4%) | 39 (3.3%) | 38 (3.6%) |
| St. Johns, NF, Canada | 127 (5.6%) | 57 (4.8%) | 70 (6.6%) |
| Rochester, NY, USA | 295 (13.1%) | 125 (10.4%) | 170 (16.1%) |
| London, ON, Canada | 58 (2.6%) | 36 (3%) | 22 (2.1%) |
| Winnipeg, MN, Canada | 181 (8%) | 85 (7.1%) | 96 (9.1%) |
| Haifa, Israel | 81 (3.6%) | 29 (2.4%) | 52 (4.9%) |
|
| |||
| Disease status: | |||
| PsA | 1327 (58.9%) | 442 (42%) | 612 (58%) |
| PsC | 927 (41.1%) | 485 (40.1%) | 715 (59.9%) |
|
| |||
| Age (years) | 52±13.8 | 52.2±13.7 | 51.6±13.9 |
|
| |||
| Ethnicity: | |||
| Caucasian | 1800 (82.4%) | 958 (82%) | 842 (82.7%) |
| South Asian | 85 (3.9%) | 65 (5.6%) | 20 (2%) |
| Chinese | 59 (2.7%) | 38 (3.3%) | 21 (2.1%) |
| Other | 240 (10.9%) | 139 (11.6%) | 171 (16.2%) |
|
| |||
| Duration of Psoriasis (years) | 21.5±15 | 21.2±14.2 | 21.8±15.8 |
|
| |||
| Duration of PsA (years) | 13.7±12.1 | 14±11.8 | 13.2±12.4 |
|
| |||
| Tender joint count* | 6.9±13.2 | 5.5±11.7 | 8.5±14.5 |
|
| |||
| Swollen joint count* | 3.9±9.8 | 3.5±9.1 | 4.4±10.5 |
|
| |||
| Damaged joint count* | 4.82±9.96 | 5.4±10.7 | 4.1±8.9 |
|
| |||
| PASI | 4.13±5.75 | 4.7±6.4 | 3.4±4.8 |
|
| |||
| Current use of NSAIDs (%) | 922 (40.9%) | 470 (39.2%) | 452 (42.9%) |
|
| |||
| Current use of DMARDs (%) | 882 (39.1%) | 442 (36.8%) | 440 (41.8%) |
|
| |||
| Current use of oral corticosteroids (%) | 91 (4%) | 46 (3.8%) | 45 (4.3%) |
|
| |||
| Current use of biologics (%) | 709 (31.5%) | 385 (32.1%) | 324 (30.7%) |
*
In PsA patients